International Scholarly Research Notices / 2012 / Article / Tab 8 / Clinical Study
The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up Table 8 Review of retrospective literature on combination of RT and IFN α -2b for nonmelanoma.
Study Site Systemic agents Radiation Outcome Maasilta et al. [11 , 12 ] lung cancer
𝑛
=
1
0
cisplatin and etoposide combined with IFN α -2b at 3 million units IM as well as 1.5 million units by jet inhaler nebulizer 1.25 Gy given twice/day to a total dose of 60 Gy severe esophagitis (
𝑛
=
4
) Hoffmann et al. [13 ] lung cancer
𝑛
=
6
cis-retinoic acid with IFN α -2b 3 million units subcutaneous 3 times/wk 50–70 Gy over 5–7 weeks mucositis 20–50% cases Selman et al. [14 ] lung cancer
𝑛
=
3
8
IFN α -2b 6 million units/day for 5 days before radiation therapy and 3 million units 4 days afterwards 55–60 Gy response 10/26 in those receiving IFN α -2b with toxicity of less fibrosis and more pneumonitis Stevens et al. [15 ] lung cancer
𝑛
=
6
IFN
𝛼
-2b 2 million units subcutaneously 3 times/week 54–66 Gy no appreciable benefit Verastegui et al. [16 ] cervix
𝑛
=
1
8
5 million units subcutaneously 3 times/week of IFN
𝛼
-2b extracavitary and intracavitary radiation, 6–10 Gy five year survival 28% compared to 7% in the control group; 94% of 17 patients developed proctitis requiring colostomy Rahn et al. [17 ] cervix
𝑛
=
4
IFN
𝛼
-2b, 3 million units subcutaneously 3 times/week as well as cis-retinoic acid various 25% Grade 3 desquamation and erythema Antonadou et al. [18 ] cervix 3 million units/day of IFN
𝛼
-2b and 13-cis retinoic acid various “well tolerated”